Opko Health Inc (NYSE:OPK) : Traders are bullish on Opko Health Inc (NYSE:OPK) as it has outperformed the S&P 500 by a wide margin of 4.44% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.26%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.54% in the last 1 week, and is up 6.13% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -40.43% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $17.51 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $9.75 and the 200 Day Moving Average price is recorded at $9.69.
The stock has recorded a 20-day Moving Average of 5.03% and the 50-Day Moving Average is 0.03%.
Opko Health Inc (NYSE:OPK): stock turned positive on Friday. Though the stock opened at $9.93, the bulls momentum made the stock top out at $10 level for the day. The stock recorded a low of $9.86 and closed the trading day at $9.87, in the green by 0.10%. The total traded volume for the day was 2,043,750. The stock had closed at $9.86 in the previous days trading.
In an insider trading activity, Frost Gamma Investments Trust, Ceo of Opko Health, Inc., executed a transaction worth $166,500 on June 30, 2016. A total of 18,000 shares were purchased at an average price of $9.25. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.